New treatment for ovarian cancer being tested

This article is more than 12 months old

Researchers are testing a new treatment for ovarian cancer which might improve the quality of life for patients with recurrences or advanced stages of the disease.

Scientists at the National Cancer Centre Singapore (NCCS) are conducting a clinical trial to test the new immunotherapy, which harnesses the body's natural defences to fight cancer.

It may have fewer side effects than conventional chemotherapy as it does not kill healthy cells.

Immunotherapy is used in treating other cancers such as lung, kidney and melanomas.

The new treatment under testing could be an option for patients with ovarian cancer if chemotherapy fails.

NCCS associate consultant Jack Chan said at a press conference yesterday that the trial is important because ovarian cancer may be on the rise.

"There has been a new case of ovarian cancer almost every day here for the last five years," he noted.

A total of 1,797 new cases were diagnosed from 2011 to 2015, according to the Singapore Cancer Registry. In that period, 634 women died of the disease.

While not as generally well-known as breast cancer, ovarian cancer is the seventh most common cause of cancer-related deaths in women here, and is the second most common gynaecological cancer among women in Singapore.

The trial is in its early phases to test the safety and effectiveness of the treatment in 20 patients with ovarian cancer.

It started in May 2017 and will recruit patients till the middle of next year.